+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.

All AgesAll Genders
59 locations
M

Actively Recruiting

This trial investigates the effects of different durations of fasting after esophageal variceal ligation therapy in patients with cirrhosis and portal hypertension. Researchers aim to compare early postoperative oral intake with a 6-hour fasting period against delayed oral intake with fasting periods of 24 or 48 hours. The study evaluates the safety and effectiveness of these approaches in reducing early postoperative rebleeding. Participants are randomly assigned to one of three groups with varying fasting durations after ligation surgery 6 hours, 24 hours, or 48 hours. The 6-hour fasting group begins with a liquid diet during the first day after surgery, progressing to semi-liquid or soft diets by days 4-7, and regular diets starting day 8. The groups fasting 24 or 48 hours receive intravenous fluids during fasting, followed by gradual diet progression similar to the 6-hour group. This study is conducted across multiple centers and uses a quadruple-blind design. During the study, participants will be monitored for early rebleeding events over 6 weeks, with additional assessments of hospital stay length, nutritional status, and non-bleeding adverse events over 4 weeks. Researchers will track diet tolerance and complications through scheduled visits and evaluations. The study runs from June 2026 to June 2027, with careful safety and outcome monitoring to understand the impact of fasting duration on recovery after variceal ligation.

Age: 18Years +All GendersPhase Not Applicable
12 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of Antiwei granules for treating the common cold, specifically the wind-cold syndrome. This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial sponsored by Tasly Pharmaceutical Group Co., Ltd. It aims to assess how well Antiwei granules work and how safe they are in adults aged 18 to 65 with recent onset of common cold symptoms. Participants will be randomly assigned to receive either Antiwei granules or a matching placebo. The treatment involves taking one sachet of granules 6 grams orally three times a day, for three days. Both groups follow the same dosing schedule, taking nine sachets total. The study compares outcomes between the Antiwei granule group and the placebo group over this short treatment period. Throughout the trial, participants will be closely monitored with assessments focusing on the cure rate after three days of treatment. Researchers will also track symptom recovery time, remission rate, disappearance of individual symptoms, traditional Chinese medicine syndrome efficacy, changes in symptom severity, occurrence of complications, emergency medication use, and overall cure of cough and cold symptoms. The total participation time includes the three-day treatment and monitoring period to evaluate treatment effects and safety.

Age: 18Years - 65YearsAll GendersPhase 3
24 locations
E

Actively Recruiting

Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.

Age: 18Years - 80YearsAll GendersPhase 3
61 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke who are undergoing endovascular thrombectomy. This phase 2, multicenter, randomized, double-blind, placebo-controlled study aims to understand how this drug affects patients treated within 24 hours of stroke onset. The trial involves adult participants aged 18 to 80 years with specific types of large-vessel occlusion in the brain. Participants will be randomly assigned to receive either anisodine hydrobromide or a placebo, both given alongside standard endovascular thrombectomy care. The drug is administered as an intravenous infusion of 2 mg diluted in saline twice daily for a total of 14 doses. The placebo group receives an equivalent volume of saline infusion on the same schedule. Both groups will be monitored during follow-up to assess treatment effects and safety. During the study, participants will undergo regular evaluations including neurological assessments using NIH Stroke Scale and modified Rankin Scale scores, along with brain imaging to measure cerebral infarct volume on day 8. Additional outcome measures at 90 days include functional independence and quality of life assessments. Safety is closely monitored, and participants are followed until study completion in March 2027.

Age: 18Years - 80YearsAll GendersPhase 2
13 locations
N

Actively Recruiting

Researchers are conducting a nationwide, multicenter observational study to establish and improve a hospital-based clinical surveillance and early warning system for respiratory syndrome pathogens. The study will include patients with respiratory syndrome from various hospital settings across seven regions in China. It aims to monitor pathogen trends, support risk assessment, and provide evidence for prevention and control strategies over several years. Participants diagnosed with respiratory syndrome will have clinical data collected every two weeks, including demographics, symptoms, diagnoses, lab tests, medications, oxygen therapy, hospital stays, ICU admissions, and outcomes. For those meeting specific diagnostic criteria, respiratory and other biospecimens will undergo a range of tests including routine pathogen tests, multiplex PCR, targeted and metagenomic sequencing, antibody and cytokine testing, and exploratory multi-omics analyses. During the study, data and specimens will be collected routinely from participants receiving clinical care. Researchers will generate national and regional surveillance reports to support early warnings and prevention efforts. The main outcomes measured include detection rates and types of respiratory pathogens and immune responses after infection or vaccination, tracked over three years. Participation involves regular data reporting through secure channels without additional treatment interventions.

All AgesAll Genders
31 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a 24-valent pneumococcal polysaccharide conjugate vaccine CRM197tetanus toxoid in individuals aged 2 months minimum 6 weeks and older. This clinical trial includes Phase I and Phase II parts, with participants divided into various age groups. The study uses randomized, blinded, and dose-escalation designs with positive controls to understand how the vaccine performs across ages from infants to older adults. The trial involves multiple vaccine doses and dose levels low, medium, high depending on age group and phase. Infants receive a primary vaccination series of three doses spaced two months apart, plus a booster dose between 12 and 15 months. Older children and adults receive one dose of the study vaccine or comparator vaccines, with random assignment to different dose groups. The study evaluates several vaccine types, including PCV24 at various doses, PPV23, and PCV13. Participants undergo screening and vaccination visits, with monitoring for adverse reactions within 7 and 30 days after each dose. Blood tests and urinalysis are performed shortly after vaccination to assess safety. Researchers measure immune responses by analyzing pneumococcal antibody levels at multiple time points, including after the primary series and booster doses. The study includes follow-up for serious adverse events up to 180 days after vaccination. Total participation duration varies by age group and dose schedule.

Age: 6Weeks +All GendersPhase 1Phase 2
2 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a combined vaccine that includes components for Diphtheria, Tetanus, Acellular Pertussis, Haemophilus influenzae type b, and Meningococcal group ACYW135 in children aged 2 months to 6 years. This Phase I clinical trial includes two parts Part One uses a randomized, partially blinded, dose-escalation and partially active-controlled design, while Part Two is a randomized, blinded, placebo-controlled study focusing on 2-month-old participants. The study involves multiple vaccine dosing schedules depending on the participants age group. Some groups receive a single dose of the combined vaccine on Day 0, while others receive three doses at 0, 2, and 4 months, followed by a booster dose between 18 and 24 months of age. The trial compares different dose levels, age groups, and also includes active comparator vaccines and placebo groups. Participants will undergo monitoring for adverse reactions within 14 days after each dose, with additional safety assessments extending up to 180 days for serious events. Researchers will evaluate immune responses by measuring specific antibodies against meningococcal groups and other vaccine components at various timepoints, including before and after booster doses. The total participation duration and detailed follow-up visits are designed to assess both safety and immunogenicity comprehensively.

Age: 2Months - 6YearsAll GendersPhase 1
1 location
E

Actively Recruiting

Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.

Age: 18Years +All GendersPhase 3
119 locations
T

Actively Recruiting

Researchers are evaluating the effectiveness and safety of combining an interleukin-6 inhibitor called tocilizumab with endovascular therapy in adults who have experienced an acute posterior circulation large-vessel occlusion stroke. This phase III clinical trial aims to see if adding tocilizumab can improve recovery outcomes for these patients. The trial is randomized, double-blind, and placebo-controlled, ensuring a rigorous comparison between treatments. Participants will receive either endovascular treatment combined with a single intravenous infusion of 240 mg tocilizumab or endovascular treatment combined with a placebo infusion. The infusion will be given immediately after randomization within 30 minutes and will take more than one hour to complete. This study involves two groups running in parallel to compare the effects of tocilizumab against placebo. During the study, participants will be assessed on their recovery using the modified Rankin Scale at 90 days as the main measure. Additional assessments include neurological improvement shortly after treatment, stroke severity scores at 7 days, and quality of life evaluations up to one year. Safety and functional outcomes will be closely monitored through various scales and indexes, with the total follow-up lasting up to one year after treatment.

Age: 18Years +All GendersPhase 3
30 locations

1-10 of 19

1